PRESS RELEASE
Notice of Preliminary Results
Guildford, UK - 10 February 2021: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its preliminary results for the year ending 31 December 2020 on 23 March 2021.
Miroslav Reljanović, Executive Chairman, and Richard Barfield, Chief Financial Officer, will host a virtual presentation and conference call for analysts at 9.00am GMT on the day of the results.
ENDS
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 402 975 |
| Miroslav Reljanović (Executive Chairman) | |
| Richard Barfield (Chief Financial Officer) | |
| | |
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
| Freddie Barnfield / Huw Jeremy (Nominated Adviser) | |
| James Black (Broker) | |
| | |
| Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
| Chris Gardner / Sue Stuart | ergomed@consilium-comms.com |
| Matthew Neal / Olivia Manser | |
| | |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
